Journal: Oncology Letters

Article Title: Iodine promotes thyroid cancer development via SPANXA1 through the PI3K/AKT signalling pathway

doi: 10.3892/ol.2019.10391

Figure Lengend Snippet: Cell proliferation evaluated by MTT assay and flow cytometry. (A) It was observed that iodine at lower concentrations (1.0×10 −4 , 1.0×10 −5 , 1.0×10 −6 , 1.0×10 −7 and 1.0×10 −8 mol/l) contributed to the proliferation of BCPAP cells, while iodine of a higher concentration (1.0×10 −3 mol/l) had a negative effect. Cells treated with iodine at 1.0×10 −6 mol/l exhibited the most pronounced changes. (B) BCPAP cell apoptosis was analysed by flow cytometry with different concentrations of iodine. BCPAP cell apoptosis, when incubated with lower concentrations of iodine (1.0×10 −4 , 1.0×10 −5 , 1.0×10 −6 , 1.0×10 −7 and 1.0×10 −8 mol/l) was significantly inhibited. Among these, the highest inhibitory effect was observed with 1.0×10 −6 mol/l iodine. A higher concentration of iodine (1.0×10 −3 mol/l) appeared to promote cell apoptosis. *P<0.05 and **P<0.01 vs. the control group. OD, optical density.

Article Snippet: BCPAP cells (3×10 5 ) were seeded into 6-well plates and incubated for 24 h. Cells were transiently transfected with synthesized SPANXA1 small interfering (si)RNAs (GCCTGCCACTGACATTGAA, 20 μM; Ribobio Co., Ltd.) using Lipofectamine ® 2000 (Invitrogen; Thermo Fisher Scientific, Inc.).

Techniques: MTT Assay, Flow Cytometry, Concentration Assay, Incubation, Control

Journal: Oncology Letters

Article Title: Iodine promotes thyroid cancer development via SPANXA1 through the PI3K/AKT signalling pathway

doi: 10.3892/ol.2019.10391

Figure Lengend Snippet: High throughput RNA-sequencing data shown as a heat map and expression of different genes in BCPAP cells treated with iodine at 1.0×10 −6 mol/l. Red represents high expression, and green represents low expression. *P<0.05 and **P<0.01 vs. the control group. KIO3, potassium iodate; BMS1P17, BMS1, ribosome biogenesis factor pseudogene 17; CALD1, caldesmon 1; H3F3BP1, H3 histone, family 3B pseudogene 1; MKI67, marker of proliferation Ki-67; SACS, sacsin molecular chaperone; SPANXA1, sperm protein associated with the nucleus, X-linked, family member A1; VCAN, versican.

Article Snippet: BCPAP cells (3×10 5 ) were seeded into 6-well plates and incubated for 24 h. Cells were transiently transfected with synthesized SPANXA1 small interfering (si)RNAs (GCCTGCCACTGACATTGAA, 20 μM; Ribobio Co., Ltd.) using Lipofectamine ® 2000 (Invitrogen; Thermo Fisher Scientific, Inc.).

Techniques: High Throughput Screening Assay, RNA Sequencing, Expressing, Control, Marker

Journal: Oncology Letters

Article Title: Iodine promotes thyroid cancer development via SPANXA1 through the PI3K/AKT signalling pathway

doi: 10.3892/ol.2019.10391

Figure Lengend Snippet: Effects of SPANXA1 on BCAP cell proliferation, migration, invasion and apoptosis. (A) Microscopy images of cells transfected with 50 nmol/l siRNA and control cells (magnification, ×400). (B) After transfection, SPANXA1 expression was decreased. (C) Proliferation of BCPAP cells treated with iodine at 1.0×10 −6 mol/l as assessed by an MTT assay; SPANXA1-knockdown BCPAP cells exhibited suppressed proliferation. Migration of BCPAP cells with downregulated SPANXA1 was evaluated using (D) a Transwell assay and (E) invasion was analysed using a scratch-wound assay. Downregulation of SPANXA1 contributed to the inhibition of migration and invasion of iodine-treated BCPAP cells. Magnification, ×20. (F) Cell apoptosis results were obtained by flow cytometry and suggested that downregulation of SPANXA1 increased apoptosis in iodine-treated BCPAP cells (1.0×10 −6 mol/l). *P<0.05 and **P<0.01 vs. the control group. NC, negative control; SPANXA1, sperm protein associated with the nucleus, X-linked, family member A1; si, small interfering; OD, optical density.

Article Snippet: BCPAP cells (3×10 5 ) were seeded into 6-well plates and incubated for 24 h. Cells were transiently transfected with synthesized SPANXA1 small interfering (si)RNAs (GCCTGCCACTGACATTGAA, 20 μM; Ribobio Co., Ltd.) using Lipofectamine ® 2000 (Invitrogen; Thermo Fisher Scientific, Inc.).

Techniques: Migration, Microscopy, Transfection, Control, Expressing, MTT Assay, Knockdown, Transwell Assay, Scratch Wound Assay Assay, Inhibition, Flow Cytometry, Negative Control

Journal: Oncology Letters

Article Title: Iodine promotes thyroid cancer development via SPANXA1 through the PI3K/AKT signalling pathway

doi: 10.3892/ol.2019.10391

Figure Lengend Snippet: Effects of the PI3K/AKT signalling pathway. (A) Downregulation of SPANXA1 suppresses PI3K and p-AKT expression in iodine-treated BCPAP cells (1.0×10 −6 mol/l). (B) PI3K and p-AKT protein expression were increased in BCPAP cells incubated with iodine at 1.0×10 −6 mol/l. Applying PI3K inhibitor LY294002 to iodine-treated cells suppressed biological behaviours, including cell proliferation, invasion and migration, but promoted apoptosis, as demonstrated by (C) MTT, (D) wound healing and (E) Transwell assays, as well as (F) flow cytometry, respectively. Magnification, ×20. *P<0.05 and **P<0.01 vs. the control group. SPANXA1, sperm protein associated with the nucleus, X-linked, family member A1; p, phosphorylated; PI3K, phosphoinositide 3-kinase; t, total.

Article Snippet: BCPAP cells (3×10 5 ) were seeded into 6-well plates and incubated for 24 h. Cells were transiently transfected with synthesized SPANXA1 small interfering (si)RNAs (GCCTGCCACTGACATTGAA, 20 μM; Ribobio Co., Ltd.) using Lipofectamine ® 2000 (Invitrogen; Thermo Fisher Scientific, Inc.).

Techniques: Expressing, Incubation, Migration, Flow Cytometry, Control

Journal: Oncology Letters

Article Title: hsa_circ_0004846 enhances the malignant phenotype of papillary thyroid carcinoma cells via the miR‑142‑3p/PELI1 axis

doi: 10.3892/ol.2025.14949

Figure Lengend Snippet: hsa_circ_0004846 is upregulated in PTC. (A) Schematic diagram of the circularization of hsa_circ_0004846. (B) Divergent primers and convergent primers were used to amplify hsa_circ_0004846 in cDNA and gDNA. (C) RT-qPCR detection of hsa_circ_0004846 in 34 PTC tissues and adjacent non-tumor tissues. (D) Expression levels of hsa_circ_0004846 in normal human thyroid cells (Nthy-ori 3–1) and thyroid cancer cells (BCPAP, TPC-1 and IHH-4). Fluorescence images of hsa_circ_0004846-overexpressing or hsa_circ_0004846-depleted (E) TPC-1 and (F) IHH-4 PTC cells. The expression levels of hsa_circ_0004846 were detected by RT-qPCR. # P<0.05. circ, circular; Lv, lentivirus; NC, negative control; PTC, papillary thyroid carcinoma; RT-qPCR, reverse transcription-quantitative PCR; sh, short hairpin.

Article Snippet: The thyroid cancer cell line BCPAP, the PTC cell line TPC-1 and the normal human thyroid cell line Nthy-ori 3–1 were purchased from iCell Bioscience Inc., and were cultured in RPMI-1640 medium (Beijing Solarbio Science & Technology Co., Ltd.) supplemented with 10% fetal bovine serum (FBS; Zhejiang Tianhang Biotechnology Co., Ltd.).

Techniques: Quantitative RT-PCR, Expressing, Fluorescence, Negative Control, Reverse Transcription, Real-time Polymerase Chain Reaction

Journal: Oncotarget

Article Title: Hyperactive ERK and persistent mTOR signaling characterize vemurafenib resistance in papillary thyroid cancer cells

doi: 10.18632/oncotarget.6779

Figure Lengend Snippet: ( A ) Cell lysates from BCPAP cells were collected after 24 hour treatment periods with gradually increasing concentrations of vemurafenib (VMR), subjected to SDS-PAGE and analyzed by Western blot for expression of phospho-ERK1/2 at the end of the 45 day experiment. ( B ) BCPAP and resistant BCPAP cells (from A) were treated with 10 μM VMR for 36 hours and viable cells were counted by trypan blue exclusion assays. **** P <.0001. ( C ) Nthy-ori 3-1 normal thyroid cells, BCPAP, and resistant BCPAP cells were treated with varying concentrations of VMR for 96 hours and then incubated with Alamar blue for 4 hours. Percent absorbance is representative of the difference between measured absorbance at 570 nm and the control absorbance at 600 nm. Data in Figure was published previously in Oncotarget. 2015; 6:39702–13.

Article Snippet: VMR-resistant BCPAP cells were created by intermittently treating BCPAP cells with increasing concentrations of VMR (Chemietek, Indianapolis, IN).

Techniques: SDS Page, Western Blot, Expressing, Incubation, Control

Journal: Oncotarget

Article Title: Hyperactive ERK and persistent mTOR signaling characterize vemurafenib resistance in papillary thyroid cancer cells

doi: 10.18632/oncotarget.6779

Figure Lengend Snippet: ( A–D ) Nthy-ori 3–1, BCPAP, 8505c, and resistant BCPAP cells were subjected to 10 μM VMR for various time points and cytoplasmic extracts were collected and analyzed by Western blot for expression of phospho-ERK1/2, CRAF, phospho-CRAF, and GAPDH (loading control). ( E ) Cytoplasmic extracts from thyroid cell lines were collected after 24 hours untreated and treated with 10 μM VMR and analyzed by Western blot for comparison of CRAF expression. After being subjected to the same 24 hour treatment, thyroid cell lines were collected and lysed using 1% NP-40 buffer. Lysates were subjected to immunoprecipitation using anti-CRAF antibody, SDS-PAGE, and Western blot analysis for CRAF.

Article Snippet: VMR-resistant BCPAP cells were created by intermittently treating BCPAP cells with increasing concentrations of VMR (Chemietek, Indianapolis, IN).

Techniques: Western Blot, Expressing, Control, Comparison, Immunoprecipitation, SDS Page

Journal: Oncotarget

Article Title: Hyperactive ERK and persistent mTOR signaling characterize vemurafenib resistance in papillary thyroid cancer cells

doi: 10.18632/oncotarget.6779

Figure Lengend Snippet: ( A ) Whole cell lysates from thyroid cell lines were collected after 24 hours +/− 10 μM VMR, subjected to SDS-PAGE, and analyzed by Western blot for expression of HER2, HER3, EGFR, and GAPDH (loading control). ( B ) Densitometry of Western blots in A was performed using ImageJ and expressed as percent expression compared to Nthy-ori 3–1 after normalizing each sample to GAPDH. ( C ) Cell lysates were collected as in A and analyzed for expression of phospho-HER3 (Tyr1197) and GAPDH as a loading control. ( D ) Densitometry of Western blots in C was performed using ImageJ and expressed as percent expression compared to untreated for BCPAP and resistant BCPAP samples.

Article Snippet: VMR-resistant BCPAP cells were created by intermittently treating BCPAP cells with increasing concentrations of VMR (Chemietek, Indianapolis, IN).

Techniques: SDS Page, Western Blot, Expressing, Control

Journal: Journal of Global Health

Article Title: Continuous Positive Airway Pressure (CPAP) for severe pneumonia in low- and middle-income countries: A systematic review of contextual factors

doi: 10.7189/jogh.12.10012

Figure Lengend Snippet: Characteristics of included studies

Article Snippet: McCollum 2019 [ ] , Bubble. Validated bCPAP system (Fisher and Paykel) , Oxygen concentrator (Airsep) , Oxygen concentrator (Airsep) , Either unvented nasal masks or nasal prongs , Integrated system's water reservoir , Integrated , Commercially available , .

Techniques: Comparison, Biomarker Discovery, Modification, Imaging, Muscles, Control, Infection, Saline, Functional Assay

Journal: Journal of Global Health

Article Title: Continuous Positive Airway Pressure (CPAP) for severe pneumonia in low- and middle-income countries: A systematic review of contextual factors

doi: 10.7189/jogh.12.10012

Figure Lengend Snippet: CPAP details of included studies

Article Snippet: McCollum 2019 [ ] , Bubble. Validated bCPAP system (Fisher and Paykel) , Oxygen concentrator (Airsep) , Oxygen concentrator (Airsep) , Either unvented nasal masks or nasal prongs , Integrated system's water reservoir , Integrated , Commercially available , .

Techniques: Saline, Sterility, Modification

Journal: Journal of Cardiothoracic Surgery

Article Title: LncRNA CASC9 facilitates papillary thyroid cancer development and doxorubicin resistance via miR-28-3p/BCL-2 axis and PI3K/AKT signaling pathway

doi: 10.1186/s13019-024-03129-4

Figure Lengend Snippet: CASC9 knockdown inhibited Dox-resistance, cell proliferation and metastasis in BCPAP/Dox and K1/Dox. ( A ) Knockdown efficiency of CASC9 using small interfere RNA in BCPAP/Dox and K1/Dox; ( B ) IC50 of BCPAP/Dox and K1/Dox after CASC9 knockdown; ( C ) Colony ability of BCPAP/Dox and K1/Dox after CASC9 knockdown and Dox treatment; ( D ) Flow cytometry was used to test the apoptotic rate in BCPAP/Dox and K1/Dox after CASC9 knockdown and Dox treatment; ( E ) Transwell assay was used to measure the migration ability in BCPAP/Dox and K1/Dox after CASC9 knockdown and Dox treatment. ** P < 0.01; *** P < 0.001

Article Snippet: NTHY-ORI 3 − 1, TPC-1, BCPAP, and K1 cell lines were bought from the China center for type culture collection (Wuhan, China).

Techniques: Knockdown, Flow Cytometry, Transwell Assay, Migration

Journal: Journal of Cardiothoracic Surgery

Article Title: LncRNA CASC9 facilitates papillary thyroid cancer development and doxorubicin resistance via miR-28-3p/BCL-2 axis and PI3K/AKT signaling pathway

doi: 10.1186/s13019-024-03129-4

Figure Lengend Snippet: miR-28-3p is a potential target of CASC9. ( A ) The potential binding site between CASC9 and miR-28-3p was predicted by Starbase; ( B ) Luciferase assay was used to confirm the binding relationship between CASC9 and miR-28-3p; ( C ) The expression of miR-28-3p in 60 PTC tissues and paired normal tissues; ( D ) qRT-PCR was used to measure the expression of miR-28-3p in BCPAP, BCPAP/Dox, K1 and K1/Dox cells. ( E ) Spearman’s correlation analysis for expression of CASC9 and miR-28-3p in 60 PTC tissues. ** P < 0.01; *** P < 0.001

Article Snippet: NTHY-ORI 3 − 1, TPC-1, BCPAP, and K1 cell lines were bought from the China center for type culture collection (Wuhan, China).

Techniques: Binding Assay, Luciferase, Expressing, Quantitative RT-PCR

Journal: Journal of Cardiothoracic Surgery

Article Title: LncRNA CASC9 facilitates papillary thyroid cancer development and doxorubicin resistance via miR-28-3p/BCL-2 axis and PI3K/AKT signaling pathway

doi: 10.1186/s13019-024-03129-4

Figure Lengend Snippet: miR-28-3p inhibitor reversed the effects of CASC9 knockdown in PTC cell lines. ( A ) The expression of miR-28-3p after CASC9 knockdown or/and miR-28-3p inhibited with Dox treatment; ( B-E ) IC50, Colony ability, apoptotic rate and migration ability of BCPAP/Dox and K1/Dox after different treatment as indicated. ** P < 0.01; *** P < 0.001

Article Snippet: NTHY-ORI 3 − 1, TPC-1, BCPAP, and K1 cell lines were bought from the China center for type culture collection (Wuhan, China).

Techniques: Knockdown, Expressing, Migration

Journal: Journal of Cardiothoracic Surgery

Article Title: LncRNA CASC9 facilitates papillary thyroid cancer development and doxorubicin resistance via miR-28-3p/BCL-2 axis and PI3K/AKT signaling pathway

doi: 10.1186/s13019-024-03129-4

Figure Lengend Snippet: CASC9 regulates BCL-2 expression via miR-28-3p. ( A ) The binding region of 3’ UTR of BCL-2 and miR-28-3p; ( B ) Luciferase assay was used to confirm the binding relationship between miR-28-3p and BCL-2; ( C ) BCL-2 protein expression in PTC patient tissues and adjacent normal tissues; ( D ) BCL-2 protein expression in NTHY-ORI 3 − 1, BCPAP, BCPAP/Dox, K1 and K1/Dox cells; ( E ) BCL-2 protein expression after CASC9 knockdown or/and miR-28-3p inhibited. ** P < 0.01; *** P < 0.001

Article Snippet: NTHY-ORI 3 − 1, TPC-1, BCPAP, and K1 cell lines were bought from the China center for type culture collection (Wuhan, China).

Techniques: Expressing, Binding Assay, Luciferase, Knockdown

Journal: Journal of Cardiothoracic Surgery

Article Title: LncRNA CASC9 facilitates papillary thyroid cancer development and doxorubicin resistance via miR-28-3p/BCL-2 axis and PI3K/AKT signaling pathway

doi: 10.1186/s13019-024-03129-4

Figure Lengend Snippet: miR-28-3p plays an important role in Dox-resistance, cell proliferation and metastasis of Dox-resistant via regulating BCL-2. BCPAP/Dox and K1/Dox cells were transfected with miR-NC, miR-28-3p, miR-28-3p + NC, miR-28-3p + BCL-2 while treated with Dox. ( A ) BCL-2 expression in different groups; ( B-E ) IC50, Colony ability, apoptotic rate and migration ability of BCPAP/Dox and K1/Dox after different treatment as indicated. ** P < 0.01; *** P < 0.001

Article Snippet: NTHY-ORI 3 − 1, TPC-1, BCPAP, and K1 cell lines were bought from the China center for type culture collection (Wuhan, China).

Techniques: Transfection, Expressing, Migration